Human HepatoPac™ Kits
Human HepatoPac™ kits are an ideal way to conduct all your DMPK, Predictive Toxicology & Mechanistic Toxicology applications. Begin dosing as early as 3 days after receiving the kit! Use our Human He...
Hepregen Corporation
Hepregen Corporation is a manufacturer of unique and proprietary bioengineered micro-liver platforms for use in environmental testing, preventive care, and product development in the
pharmaceutical and biopharmaceutical, diagnostic, cosmetics, and chemical industries. The Company’s
micro-liver HepatoPac™ and HepatoMune™ cell-based assays are driving a paradigm shift in drug
development. The utility of Hepregen’s human, rat, monkey, dog, and multi-species/multi-donor HepatoPac™ and HepatoMune™ products has been validated in collaboration with investigators at several well-known pharmaceutical companies. Additionally, new applications for these products are being tested by Hepregen, its pharmaceutical company customers, and its academic and business partners. Hepregen was founded and capitalized by Battelle Ventures with technology licensed from the Massachusetts Institute of Technology. The technology was developed by Professor Sangeeta Bhatia, who is a world renowned expert and leader in liver bioengineering for life science and therapeutic applications.
Hepregen DMPK Services
Hepregen offers a range of DMPK services using their HepatoPac™ co-culture system. Hepregen has experienced scientific staff which work closely with our clients to design assays that meet their needs...
Hepregan Toxicology Services
Hepregen offers a range of toxicology services using their HepatoPac™ co-culture or Kupffer Cell Model systems. Hepregen's experienced scientific staff work closely with clients to design assays to m...
Browse Products by Field
Hepregen Corporation is a manufacturer of unique and proprietary bioengineered micro-liver platforms for use in environmental testing, preventive care, and product development in the
pharmaceutical and biopharmaceutical, diagnostic, cosmetics, and chemical industries. The Company’s
micro-liver HepatoPac™ and HepatoMune™ cell-based assays are driving a paradigm shift in drug
development. The utility of Hepregen’s human, rat, monkey, dog, and multi-species/multi-donor HepatoPac™ and HepatoMune™ products has been validated in collaboration with investigators at several well-known pharmaceutical companies. Additionally, new applications for these products are being tested by Hepregen, its pharmaceutical company customers, and its academic and business partners. Hepregen was founded and capitalized by Battelle Ventures with technology licensed from the Massachusetts Institute of Technology. The technology was developed by Professor Sangeeta Bhatia, who is a world renowned expert and leader in liver bioengineering for life science and therapeutic applications.